Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Me

The Prescription Drug User Fee Act (PDUFA) target action date is May 10, 2023PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the Joint Meeting of the Psychopharmacologic Drugs Advisory C...

Related Keywords

Mansfield , Nunavut , Canada , Italy , Lerdrup , Midtjylland , Denmark , Tokyo , Japan , United States , California , France , Robert Murphy , Clin Neurosci , John Kraus , Linkedin , Health Canada , Otsuka Pharmaceutical Company Ltd , Drug Administration , Meeting Of The Psychopharmacologic Drugs Advisory Committee , Central Nervous System Drugs Advisory Committee , International Psychogeriatric Association , Otsuka Holdings Co Ltd , Otsuka Pharmaceutical Development Commercialization Inc , Twitter , Lundbeck Pharmaceuticals , Corporate Communications , Lundbeck , Otsuka Pharmaceutical Co Ltd , Otsuka America Pharmaceutical Inc , H Lundbeck , Prescription Drug User Fee Act , Otsuka Pharmaceutical Development , Joint Meeting , Psychopharmacologic Drugs Advisory Committee , New Drug Application , Drug User Fee Act , Cohen Mansfield Agitation Inventory , Total Score , About Agitation Associated , Adverse Events , Including Stroke , Malignant Syndrome , Diabetes Mellitus , Temperature Dysregulation , Motor Impairment , Depressive Disorder , Otsuka America Pharmaceutical , Otsuka Pharmaceutical Company , Ageing Res , Intj Geriatr Psychiatry , Pharmacol Exp , America Pharmaceutical ,